FivePrime Therapeutics, Inc. Announces That Human Genome Sciences Files U.S. IND for HGS1036/FP-1039 FGF Ligand Trap

Published: Jun 04, 2012

SOUTH SAN FRANCISCO, Calif., June 4, 2012 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (FivePrime), a leader in the discovery and development of innovative biologics, announced today that Human Genome Sciences (HGS) has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration to initiate a Phase 1b human clinical trial of HGS1036/FP-1039 in combination with multiple anti-cancer regimens.

Back to news